Paragon 28, Inc. (FNA)
(Delayed Data from NYSE)
$10.53 USD
+0.76 (7.78%)
Updated May 3, 2024 04:00 PM ET
After-Market: $10.53 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.53 USD
+0.76 (7.78%)
Updated May 3, 2024 04:00 PM ET
After-Market: $10.53 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
Zacks News
Paragon 28 (FNA) Expands Syndesmotic Repair Line With New Launch
by Zacks Equity Research
The dynamic functionality of Paragon 28's (FNA) Grappler R3INFORCE System sets it apart from traditional static repair systems, offering a more physiological and anatomical reconstruction option.
Paragon 28, Inc. (FNA) Moves 16.2% Higher: Will This Strength Last?
by Zacks Equity Research
Paragon 28, Inc. (FNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Sensus Healthcare, Inc. (SRTS) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of 116.67% and 3.89%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Paragon 28 (FNA) BEAST Cortical Fibers Launch Boosts Biologics
by Zacks Equity Research
Paragon 28's (FNA) BEAST Cortical Fibers' advanced processing capability ensures the preservation of native bone morphogenic proteins and other growth factors crucial for bone formation.
Paragon 28 (FNA) New Staple System Expands Ankle Device Line
by Zacks Equity Research
Paragon 28's (FNA) JAWS Great White Staple System is claimed to have 400 times greater fatigue life compared to competitors under similar load conditions.
Paragon 28, Inc. (FNA) Surges 12.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Paragon 28, Inc. (FNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Paragon 28, Inc. (FNA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Paragon 28, Inc. (FNA) delivered earnings and revenue surprises of -44.44% and 2.10%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
PROCEPT BioRobotics Corporation (PRCT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
PROCEPT BioRobotics Corporation (PRCT) delivered earnings and revenue surprises of 1.75% and 9.42%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Paragon 28, Inc. (FNA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Paragon 28, Inc. (FNA) delivered earnings and revenue surprises of -10% and 3.53%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Intuitive Surgical, Inc. (ISRG) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) delivered earnings and revenue surprises of 3.36% and 6.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Paragon 28, Inc. (FNA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Paragon 28, Inc. (FNA) delivered earnings and revenue surprises of -466.67% and 2.03%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
OrthoPediatrics (KIDS) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of -45.45% and 0.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Paragon 28, Inc. (FNA) Q4 Earnings Expected to Decline
by Zacks Equity Research
Paragon 28, Inc. (FNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Think Paragon 28, Inc. (FNA) Could Surge 34%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 33.5% upside potential for Paragon 28, Inc. (FNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is EDAP TMS (EDAP) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how EDAP TMS S.A. (EDAP) and Paragon 28, Inc. (FNA) have performed compared to their sector so far this year.
Paragon 28, Inc. (FNA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Paragon 28, Inc. (FNA) delivered earnings and revenue surprises of 0% and 8.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Steris (STE) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of -0.50% and 1.79%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Tactile Systems Technology (TCMD) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of 200% and 8.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Aileron Therapeutics (ALRN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aileron Therapeutics, Inc. (ALRN) and Paragon 28, Inc. (FNA) have performed compared to their sector so far this year.
Can Paragon 28, Inc. (FNA) Climb 63% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 63.3% upside potential for Paragon 28, Inc. (FNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Paragon 28, Inc. (FNA) Upgraded to Buy: Here's Why
by Zacks Equity Research
Paragon 28, Inc. (FNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Think Paragon 28, Inc. (FNA) Could Surge 64%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 63.7% upside potential for Paragon 28, Inc. (FNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Has Paragon 28, Inc. (FNA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Paragon 28, Inc. (FNA) and Gamida Cell (GMDA) have performed compared to their sector so far this year.